Regenxbio (RGNX) Common Equity (2014 - 2025)

Regenxbio's Common Equity history runs 12 years deep, the most recent figure standing at $102.7 million for Q4 2025.

• On a quarterly basis, Common Equity fell 60.43% year-over-year to $102.7 million in Q4 2025; TTM through Dec 2025 was $102.7 million, a 60.43% decrease from a year earlier, with the FY2025 full-year figure at $102.7 million, down 60.43% from the prior year.
• Common Equity eased to $102.7 million in Q4 2025 per RGNX's latest filing, from $161.5 million in the prior quarter.
• Across five years, Common Equity topped out at $764.3 million in Q4 2021 and bottomed at $102.7 million in Q4 2025.
• The 5-year median for Common Equity is $398.3 million (2023), against an average of $414.3 million.
• Across the five-year window, Common Equity surged 102.33% in 2021 and slumped 60.43% in 2025, its largest moves.
• Year by year, Common Equity stood at $764.3 million in 2021, then sank by 32.46% to $516.2 million in 2022, then tumbled by 39.61% to $311.7 million in 2023, then fell by 16.71% to $259.7 million in 2024, then slumped by 60.43% to $102.7 million in 2025.
• Per Business Quant, the three latest RGNX Common Equity figures stand at $102.7 million (Q4 2025), $161.5 million (Q3 2025), and $213.7 million (Q2 2025).